Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.3 It was founded by Michael D. West.1 Its shares trade on Nasdaq under the symbol GERN.1Wikipedia text CC BY-SA 4.0
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Out of $237.0K in revenue.98 The company lost money this year.
Financial statements
Revenue11129$237.0K in 2023−48% since 2019Operating income11129108-$193.9M in 2023+167% since 2019Net income11129108-$184.1M in 2023+169% since 2019
Revenue1314$57.5M in Q2 FY2026+11% since Q1 FY2026Operating income1314-$12.5M in Q2 FY2026Net income1314-$16.7M in Q2 FY2026+358% since Q1 FY2026
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Cost of goods sold
$4.7M
$1.3M
$0
Research and development
$71.4M
$103.7M
$125.0M
Selling, general and administrative
$159.3M
$145.7M
$69.1M
Restructuring charges
$17.0M
$0
$0
Total costs and operating expenses
$252.5M
$250.7M
$194.2M
Loss from operations
-$68.6M
-$173.7M
-$193.9M
Interest income
$18.1M
$19.6M
$18.2M
Interest expense
-$32.7M
-$18.5M
-$8.3M
Other income (expense), net
-$375.0K
-$236.0K
-$23.0K
Loss on extinguishment of debt
$0
-$1.7M
$0
Net loss
-$83.5M
-$174.6M
-$184.1M
Basic net loss per share (in dollars per share)
-$0.13
-$0.27
-$0.32
Diluted net loss per share (in dollars per share)
-$0.13
-$0.27
-$0.32
Weighted average common shares outstanding, basic (in shares)
666.7M shares
646.0M shares
570.6M shares
Weighted average common shares outstanding, diluted (in shares)
666.7M shares
646.0M shares
570.6M shares
No quarter-by-quarter statement was filed.
Total assets151112910$394.1M in 2023+138% since 2019Total liabilities151112910$146.1M in 2023+381% since 2019Shareholders’ equity129108$247.9M in 2023+83% since 2019Cash151112910$70.0M in 2023+413% since 2019Long-term debt1112910$35.1M in 2023+46% since 2020
Total assets1314$519.0M in Q2 FY2026−9% since Q1 FY2025Total liabilities1314$300.4M in Q2 FY2026−13% since Q1 FY2025Shareholders’ equity1314$218.6M in Q2 FY2026−3% since Q1 FY2025Cash1314$62.6M in Q2 FY2026−19% since Q1 FY2025Long-term debt1314$120.1M in Q2 FY2026+0% since Q1 FY2025
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
2023-05-31
2023-04-30
Cash and cash equivalents
$77.6M
$79.0M
Restricted cash
$1.9M
$1.9M
Marketable securities
$280.4M
$327.6M
Accounts receivable, net
$37.0M
$35.9M
Interest and other receivables
$2.2M
$2.9M
Inventory
$116.6M
$38.7M
Prepaid and other current assets
$4.6M
$5.1M
Total current assets
$520.3M
$491.0M
Noncurrent marketable securities
$41.3M
$94.5M
Property and equipment, net
$884.0K
$1.3M
Operating leases, right-of-use assets
$2.2M
$2.9M
Deposits and other assets
$5.9M
$4.1M
Total assets
$570.5M
$593.8M
Accounts payable
$11.3M
$8.6M
Accrued compensation and benefits
$30.5M
$22.8M
Operating lease liabilities
$1.0M
$974.0K
Liability related to sale of future royalties
$17.4M
$20.4M
Accrued liabilities
$51.3M
$35.5M
Total current liabilities
$111.5M
$88.3M
Noncurrent operating lease liabilities
$1.4M
$2.3M
Noncurrent liability related to sale of future royalties
$112.1M
$104.4M
Noncurrent debt
$119.5M
$118.5M
Total liabilities
$344.7M
$313.5M
Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024
$0
$0
Common stock, $0.001 par value; 1,350,000,000 shares authorized; 639,856,222 and 606,387,666 shares issued and outstanding at December 31, 2025 and 2024, respectively
$640.0K
$606.0K
Additional paid-in capital
$2.1B
$2.1B
Accumulated deficit
-$1.9B
-$1.8B
Accumulated other comprehensive income
$269.0K
$261.0K
Total stockholders' equity
$225.9M
$280.3M
$247.9M
Total liabilities and stockholders' equity
$570.5M
$593.8M
Preferred stock, par value (in dollars per share)
$0.00
$0.00
Preferred stock, authorized (in shares)
3.0M shares
3.0M shares
Preferred stock, issued (in shares)
0 shares
0 shares
Preferred stock, outstanding (in shares)
0 shares
0 shares
Common stock, par value (in dollars per share)
$0.00
$0.00
Common stock, authorized (in shares)
1.4B shares
1.4B shares
1.4B shares
675.0M shares
Common stock, issued (in shares)
639.9M shares
606.4M shares
Common stock, outstanding (in shares)
639.9M shares
606.4M shares
Period ending
2025-12-31
2024-12-31
2023-12-31
2023-05-31
2023-04-30
2022-12-31
Cash and cash equivalents
$77.6M
$79.0M
Restricted cash
$1.9M
$1.9M
Marketable securities
$280.4M
$327.6M
Accounts receivable, net
$37.0M
$35.9M
Interest and other receivables
$2.2M
$2.9M
Inventory
$116.6M
$38.7M
Prepaid and other current assets
$4.6M
$5.1M
Total current assets
$520.3M
$491.0M
Noncurrent marketable securities
$41.3M
$94.5M
Property and equipment, net
$884.0K
$1.3M
Operating leases, right-of-use assets
$2.2M
$2.9M
Deposits and other assets
$5.9M
$4.1M
Total assets
$570.5M
$593.8M
Accounts payable
$11.3M
$8.6M
Accrued compensation and benefits
$30.5M
$22.8M
Operating lease liabilities
$1.0M
$974.0K
Liability related to sale of future royalties
$17.4M
$20.4M
Accrued liabilities
$51.3M
$35.5M
Total current liabilities
$111.5M
$88.3M
Noncurrent operating lease liabilities
$1.4M
$2.3M
Noncurrent liability related to sale of future royalties
$112.1M
$104.4M
Noncurrent debt
$119.5M
$118.5M
Total liabilities
$344.7M
$313.5M
Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024
$0
$0
Common stock, $0.001 par value; 1,350,000,000 shares authorized; 639,856,222 and 606,387,666 shares issued and outstanding at December 31, 2025 and 2024, respectively
$640.0K
$606.0K
Additional paid-in capital
$2.1B
$2.1B
Accumulated deficit
-$1.9B
-$1.8B
Accumulated other comprehensive income
$269.0K
$261.0K
Total stockholders' equity
$225.9M
$280.3M
$247.9M
$80.0M
Total liabilities and stockholders' equity
$570.5M
$593.8M
Preferred stock, par value (in dollars per share)
$0.00
$0.00
Preferred stock, authorized (in shares)
3.0M shares
3.0M shares
Preferred stock, issued (in shares)
0 shares
0 shares
Preferred stock, outstanding (in shares)
0 shares
0 shares
Common stock, par value (in dollars per share)
$0.00
$0.00
Common stock, authorized (in shares)
1.4B shares
1.4B shares
1.4B shares
675.0M shares
Common stock, issued (in shares)
639.9M shares
606.4M shares
Common stock, outstanding (in shares)
639.9M shares
606.4M shares
Cash from operations11129108-$167.7M in 2023+283% since 2019Capital spending1112910$830.0K in 2023+101% since 2019Free cash flow11129108-$168.6M in 2023+281% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Net loss
-$83.5M
-$174.6M
-$184.1M
Depreciation and amortization
$474.0K
$546.0K
$442.0K
Accretion and amortization on investments, net
-$6.9M
-$9.7M
-$11.2M
Amortization of debt issuance costs/debt discount
$1.1M
-$3.1M
$1.1M
Non-cash interest expense on liabilities for sales of future royalties
$18.9M
$5.3M
$0
Loss of extinguishment of debt
$0
$1.7M
$0
Stock-based compensation for services by non-employees
$88.0K
$135.0K
$828.0K
Stock-based compensation for employees and directors
$26.7M
$31.2M
$18.5M
Amortization of right-of-use assets
$730.0K
$675.0K
$591.0K
Increase in allowance for doubtful accounts
-$50.0K
-$251.0K
$0
Inventory
-$77.9M
-$38.0M
$0
Accounts receivable, net
-$991.0K
-$35.7M
$0
Interest and other receivables
$614.0K
-$1.2M
$1.5M
Prepaid expenses and other assets
$443.0K
-$175.0K
-$886.0K
Deposit and other assets
-$1.9M
$618.0K
$692.0K
Accounts payable
$2.7M
$2.4M
-$4.0M
Accrued compensation and benefits
$7.7M
$9.0M
$2.2M
Royalty financing obligation
-$14.2M
-$2.2M
$0
Accrued liabilities
$15.8M
-$4.8M
$7.2M
Operating lease liabilities
-$796.0K
-$715.0K
-$640.0K
Net cash used in operating activities
-$111.0M
-$218.6M
-$167.7M
Purchases of property and equipment
-$49.0K
-$680.0K
-$830.0K
Purchases of marketable securities
-$304.4M
-$476.9M
-$475.6M
Proceeds from maturities and sales of marketable securities
$411.7M
$371.6M
$296.1M
Net cash provided by (used in) investing activities
$107.2M
-$106.0M
-$180.3M
Proceeds from issuances of common stock from equity plans
$2.3M
$32.7M
$13.1M
Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs
$0
$140.7M
$213.3M
Proceeds from exercise of warrants
$0
$1.4M
$105.9M
Proceeds from sale of future royalties
$0
$125.0M
$0
Proceeds from debt financing, net of paid debt issuance costs and debt discounts
$0
$121.1M
$29.7M
Repayment of debt
$0
-$86.6M
$0
Net cash provided by financing activities
$2.3M
$334.4M
$362.0M
Net effect of exchange rates on cash, cash equivalents and restricted cash
$87.0K
-$12.0K
-$27.0K
Net increase (decrease) in cash, cash equivalents and restricted cash
Geron Corporation sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Geron Corporation
RA CAPITAL MANAGEMENT, L.P.Filed SCHEDULE 13G/A on Geron Corporation, latest Aug 14, 2026 (6 filings since Feb 14, 2022)
State Street CorporationFiled SCHEDULE 13G on Geron Corporation, latest Aug 7, 2026 (3 filings since Feb 1, 2023)
Deep Track Capital, LPFiled SCHEDULE 13G/A on Geron Corporation, latest May 15, 2026 (7 filings since Jan 13, 2023)
EcoR1 Capital, LLCFiled SC 13G/A on Geron Corporation, latest Feb 14, 2022
Geron CorporationMenlo Park, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Geron Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.
The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).
In 2017, Geron staff received the highest median pay in California, at $500,250.
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
288 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 139 insider forms, 30 large holders, 39 other. The latest 20:
18 open-market trades by officers, directors and large owners since October 2021: 5 buys and 13 sales. Grants, option exercises and gifts are left out.
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
Year
Executive
Age
Salary
Total pay
2025
Harout SemerjianPresident and Chief Executive Officer (as of August 7, 2025)
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
